Tag Archive for: enzalutamide

Final OS Data from EMBARK Phase 3 Trial: Enzalutamide With ADT for Men at Risk of BRPC

Data from the phase 3 EMBARK trial, combining enzalutamide with standard hormone therapy, recently published in The New England Journal of Medicine and presented at the 2025 European Society for Medical Oncology (ESMO) Congress, reveal that this combination reduces the risk of death by more than 40% over eight years compared to hormone therapy alone. […]

ENZARAD Trial Shows Selective Gains for Node-Positive Prostate Cancer With Enzalutamide Intensification

The final results of the phase 3 ENZARAD study, presented at the European Society for Medical Oncology (ESMO) Congress 2025, reveal that intensifying androgen deprivation therapy (ADT) with enzalutamide does not significantly improve metastasis-free survival (MFS) in the overall population of men with high-risk localized or locally advanced prostate cancer. Conducted across eight countries and […]

Efficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer